Financial Summary:
| Three Months Ended | ||||||||||||
$ in millions | 2026 | 2025 | % Change | |||||||||
Revenue | $ | 20.8 | $ | 15.1 | 37.9 | % | ||||||
Gross Profit | $ | 8.6 | $ | 4.5 | 91.9 | % | ||||||
Operating Expenses | $ | 10.8 | $ | 7.0 | 54.1 | % | ||||||
Net Income (Loss) | $ | (1.7 | ) | $ | (2.9 | ) | 41.2 | % | ||||
Adjusted EBITDA* (non-GAAP) | $ | 1.3 | $ | 0.4 | 252.1 | % | ||||||
*Reconciliation of this non-GAAP financial measure is provided below. Percentage change for net loss is calculated on absolute values.
First Quarter Fiscal 2027 & Subsequent Highlights:
- Grew order backlog to a record of approximately
$132.9 million as ofSeptember 30, 2026 , up 20% from$110.9 million atJune 30, 2026 and up 54% from$86.0 million atSeptember 30, 2025 , with approximately$110.8 million requested by customers for delivery within the next twelve months. - Secured more than
$30 million of follow-on counter-unmanned aircraft system ("C-UAS") orders from July throughOctober 2026 , including more than$19 million of optical assembly orders from a leading C-UAS and defense systems supplier - double that customer's total for all of fiscal 2026 - and an$11 million infrared camera order from a leading global technology customer. - Received an order in
October 2026 from a key defense customer for over 50,000 optical assemblies for drone camera systems as theU.S . and its allies rapidly scale up drone procurement. - Awarded a funded prototype agreement under the
Department of War's Critical Low-risk Electro-optic Alternatives for Resilience ("CLEAR") program to further develop BlackDiamond™ chalcogenide glass and optics as germanium alternatives for defense electro-optic and infrared ("EO/IR") systems. - Strengthened imaging systems leadership with the promotion of
Michael Amorelli to VP Engineering, Imaging Systems, and the appointment of formerAnduril Industries production leaderScott Payette as Vice President of LightPath and General Manager ofG5 Infrared LLC ("G5 Infrared"). - Completed the previously announced sale of the Company's
China subsidiary,LightPath Optical Instrumentation (Zhenjiang) Co., Ltd. ("LPOIZ"), as ofOctober 30, 2026 , as a result of which LightPath no longer has facilities or operations based inChina .
Management Commentary
"The composition of our revenue continues to be more favorable as well. Revenue grew 38% year-over-year to
"Demand continues to build in optical assemblies and infrared cameras, two of our three projected growth pillars alongside large defense programs. A leading C-UAS supplier has placed more than
"Our focus for the balance of fiscal 2027 is converting this backlog on schedule. We invested ahead of scheduled deliveries during the quarter, building inventory of critical materials and work-in-process and adding manufacturing capacity, including glass fabrication. With a strong balance sheet, a strengthened imaging systems leadership team under
First Quarter Fiscal 2027 Financial Results
Revenue for the first quarter of fiscal 2027 increased 38% to
Product Group Revenue | First Quarter of | First Quarter of | ||||||||||
($ in millions)** | Fiscal 2027 | Fiscal 2026 | % Change | |||||||||
Infrared ("IR") Components | $ | 4.7 | $ | 4.1 | 15 | % | ||||||
Visible Components | $ | 4.6 | $ | 3.8 | 19 | % | ||||||
Assemblies & Modules | $ | 10.5 | $ | 6.0 | 76 | % | ||||||
| $ | 0.9 | $ | 1.1 | (18 | )% | |||||||
** Numbers may not foot due to rounding. Certain fiscal 2026 amounts have been reclassified from infrared components to assemblies and modules to conform to the current classification.
Assemblies and modules revenue grew 76% to
Visible components revenue increased 19%, reflecting higher sales to industrial customers in
Gross profit increased 92% to
Operating expenses for the first quarter of fiscal 2027 were
Net loss for the first quarter of fiscal 2027 improved to
Adjusted EBITDA* for the first quarter of fiscal 2027 increased to
Cash and cash equivalents as of
Total backlog as of
First Quarter Fiscal 2027 Earnings Call
Management will host an investor conference call at
Q1 FY2027 Earnings Conference Call
Date:
Time:
International Dial-in: 1-203-518-9783
Conference ID: LIGHT
Webcast: LPTH Q1 FY2027 Earnings Conference Call
Please join at least five minutes before the start of the call to ensure timely participation.
A playback of the call will be available through
About
*Use of Non-GAAP Financial Measures
To provide investors with additional information regarding financial results, this press release includes references to EBITDA and adjusted EBITDA, which are non-GAAP financial measures. The Company calculates EBITDA by adjusting net income to exclude net interest expense, income tax expense or benefit, depreciation, and amortization. We also calculate adjusted EBITDA, which excludes, as applicable: (1) stock compensation expenses; (2) the loss on extinguishment of debt; (3) the effect of non-cash income or expenses associated with the fair value adjustments related to the acquisition earnout liabilities; (4) acquisition costs, including legal fees and due diligence; and (5) the effect of foreign exchange gains or losses.
A "non-GAAP financial measure" is generally defined as a numerical measure of a company's historical or future performance that excludes or includes amounts, or is subject to adjustments, so as to be different from the most directly comparable measure calculated and presented in accordance with GAAP. The Company's management believes that these non-GAAP financial measures, when considered together with the GAAP financial measures, provide information that is useful to investors in understanding period-over-period operating results separate and apart from items that may, or could, have a disproportionately positive or negative impact on results in any particular period. Management also believes that these non-GAAP financial measures enhance the ability of investors to analyze underlying business operations and understand performance. In addition, management may utilize these non-GAAP financial measures as guides in forecasting, budgeting, and planning. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures presented in accordance with GAAP. A reconciliation of these non-GAAP financial measures with the most directly comparable financial measures calculated in accordance with GAAP is presented in the table below.
Reconciliation of Non-GAAP Financial Measures and Regulation G Disclosure
| (unaudited) | ||||||||
| Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
Net loss | $ | (1,700,754 | ) | $ | (2,893,002 | ) | ||
Depreciation and amortization | 1,479,568 | 1,218,948 | ||||||
Income tax provision | 123,492 | 81,270 | ||||||
Interest (income) expense | (670,652 | ) | 268,853 | |||||
EBITDA | $ | (768,346 | ) | $ | (1,323,931 | ) | ||
Stock-based compensation | 1,801,199 | 359,661 | ||||||
Change in fair value of acquisition earnout liabilities | 196,633 | 1,282,529 | ||||||
Foreign exchange loss | 40,848 | 42,543 | ||||||
Adjusted EBITDA | $ | 1,270,334 | $ | 360,802 | ||||
% of revenue | 6 | % | 2 | % | ||||
Forward-Looking Statements
This press release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "guidance," "plan," "estimate," "will," "would," "project," "maintain," "intend," "expect," "anticipate," "prospect," "strategy," "future," "likely," "may," "should," "believe," "continue," "opportunity," "potential," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, without limitation, statements regarding: (i) the Company's ability to convert its backlog into revenue and the timing of such conversion; (ii) expectations regarding demand for germanium alternatives, including the Company's BlackDiamond™ materials, and the effect of
Investor Relations Contact
Managing Director
LPTH@mzgroup.us
+1 (949) 259-4987
Condensed Consolidated Balance Sheets
(unaudited)
| 2026 | 2026 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 82,934,165 | $ | 93,204,655 | ||||
Trade accounts receivable, net of allowance of | 15,182,690 | 15,112,908 | ||||||
Inventories, net | 31,486,533 | 18,005,559 | ||||||
Prepaid expenses and deposits | 2,420,098 | 3,457,300 | ||||||
Other current assets | 132,534 | 116,028 | ||||||
Total current assets | 132,156,020 | 129,896,450 | ||||||
Property and equipment, net | 20,833,058 | 19,363,026 | ||||||
Operating lease right-of-use assets | 7,828,475 | 8,115,887 | ||||||
Intangible assets, net | 16,679,575 | 17,134,601 | ||||||
| 19,315,177 | 19,315,177 | |||||||
Deferred tax assets, net | 85,902 | 85,902 | ||||||
Other assets | 93,136 | 96,578 | ||||||
Total assets | $ | 196,991,343 | $ | 194,007,621 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 10,954,633 | $ | 7,686,144 | ||||
Accrued liabilities | 11,889,102 | 12,779,784 | ||||||
Accrued payroll and benefits | 2,793,391 | 4,139,586 | ||||||
Operating lease liabilities, current | 1,202,483 | 1,189,908 | ||||||
Loans payable, current portion | 111,815 | 112,317 | ||||||
Finance lease obligation, current portion | 365,923 | 269,414 | ||||||
Total current liabilities | 27,317,347 | 26,177,153 | ||||||
Deferred tax liabilities, net | 95,994 | 95,084 | ||||||
Finance lease obligation, less current portion | 803,150 | 392,796 | ||||||
Operating lease liabilities, noncurrent | 8,569,553 | 8,888,227 | ||||||
Loans payable, less current portion | 46,589 | 74,878 | ||||||
Total liabilities | 36,832,633 | 35,628,138 | ||||||
Commitments and Contingencies | ||||||||
Series G Convertible Preferred Stock; | $ | 8,906,686 | $ | 8,906,686 | ||||
Stockholders' equity: | ||||||||
Preferred stock: Series D, | - | - | ||||||
Common stock: Class A, | 700,877 | 699,630 | ||||||
Additional paid-in capital | 402,146,557 | 398,726,619 | ||||||
Accumulated other comprehensive income | 1,367,664 | 1,308,868 | ||||||
Accumulated deficit | (252,963,074 | ) | (251,262,320 | ) | ||||
Total stockholders' equity | 151,252,024 | 149,472,797 | ||||||
Total liabilities, convertible preferred stock and stockholders' equity | $ | 196,991,343 | $ | 194,007,621 | ||||
Condensed Consolidated Statements of Comprehensive Income (Loss)
(unaudited)
| Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
Revenue, net | $ | 20,762,654 | $ | 15,058,281 | ||||
Cost of sales | 12,160,790 | 10,575,709 | ||||||
Gross profit | 8,601,864 | 4,482,572 | ||||||
Operating expenses: | ||||||||
Selling, general and administrative | 8,048,205 | 4,383,870 | ||||||
New product development | 2,036,377 | 867,428 | ||||||
Amortization of intangible assets | 455,026 | 450,524 | ||||||
Change in fair value of acquisition earnout liabilities | 196,633 | 1,282,529 | ||||||
Loss on disposal of property and equipment | 30,849 | 3,999 | ||||||
Total operating expenses | 10,767,090 | 6,988,350 | ||||||
Operating loss | (2,165,226 | ) | (2,505,778 | ) | ||||
Other income (expense): | ||||||||
Interest income (expense), net | 670,652 | (268,853 | ) | |||||
Other expense, net | (82,688 | ) | (37,101 | ) | ||||
Total other income (expense) | 587,964 | (305,954 | ) | |||||
Loss before income taxes | (1,577,262 | ) | (2,811,732 | ) | ||||
Income tax provision | 123,492 | 81,270 | ||||||
Net loss | $ | (1,700,754 | ) | $ | (2,893,002 | ) | ||
Foreign currency translation adjustment | 58,796 | 92,383 | ||||||
Comprehensive loss | $ | (1,641,958 | ) | $ | (2,800,619 | ) | ||
Loss per common share (basic) | $ | (0.02 | ) | $ | (0.07 | ) | ||
Number of shares used in per share calculation (basic) | 70,010,938 | 43,287,933 | ||||||
Loss per common share (diluted) | $ | (0.02 | ) | $ | (0.07 | ) | ||
Number of shares used in per share calculation (diluted) | 70,010,938 | 43,287,933 | ||||||
Condensed Consolidated Statements of Changes in Stockholders' Equity
(unaudited)
| Temporary Equity | Accumulated | |||||||||||||||||||||||||||||||
| Series G Convertible | Class A | Additional | Other | Total | ||||||||||||||||||||||||||||
| Preferred Stock | Common Stock | Paid-in | Comprehensive | Accumulated | Stockholders' | |||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Income | Deficit | Equity | |||||||||||||||||||||||||
Balances at | 6,492 | $ | 8,906,686 | 69,963,045 | $ | 699,630 | $ | 398,726,619 | $ | 1,308,868 | $ | (251,262,320 | ) | $ | 149,472,797 | |||||||||||||||||
Issuance of common stock for: | ||||||||||||||||||||||||||||||||
Employee Stock Purchase Plan | - | - | 2,713 | 27 | 44,330 | - | - | 44,357 | ||||||||||||||||||||||||
Exercise of stock options, RSUs & RSAs, net | - | - | 661 | 7 | (7 | ) | - | - | - | |||||||||||||||||||||||
Issuance of common stock for acquisition of Amorphous | - | - | 121,259 | 1,213 | 1,621,666 | - | - | 1,622,879 | ||||||||||||||||||||||||
Stock-based compensation on stock options, RSUs & RSAs | - | - | - | - | 1,753,949 | - | - | 1,753,949 | ||||||||||||||||||||||||
Foreign currency translation adjustment | - | - | - | - | - | 58,796 | - | 58,796 | ||||||||||||||||||||||||
Net loss | - | - | - | - | - | - | (1,700,754 | ) | (1,700,754 | ) | ||||||||||||||||||||||
Balances at | 6,492 | $ | 8,906,686 | 70,087,678 | $ | 700,877 | $ | 402,146,557 | $ | 1,367,664 | $ | (252,963,074 | ) | $ | 151,252,024 | |||||||||||||||||
Balances at | 24,956 | $ | 34,232,510 | 42,949,307 | $ | 429,493 | $ | 244,953,346 | $ | 978,686 | $ | (230,716,757 | ) | $ | 15,644,768 | |||||||||||||||||
Issuance of common stock for: | ||||||||||||||||||||||||||||||||
Exercise of stock options, RSUs & RSAs, net | - | - | 8,583 | 86 | (86 | ) | - | - | - | |||||||||||||||||||||||
Issuance of common stock under private equity placement | - | - | 1,600,000 | 16,000 | 7,878,045 | - | - | 7,894,045 | ||||||||||||||||||||||||
Issuance of common stock for acquisition of Visimid | - | - | 112,323 | 1,123 | 348,877 | - | - | 350,000 | ||||||||||||||||||||||||
Stock-based compensation on stock options, RSUs & RSAs | - | - | - | - | 349,624 | - | - | 349,624 | ||||||||||||||||||||||||
Foreign currency translation adjustment | - | - | - | - | - | 92,383 | - | 92,383 | ||||||||||||||||||||||||
Net loss | - | - | - | - | - | - | (2,893,002 | ) | (2,893,002 | ) | ||||||||||||||||||||||
Balances at | 24,956 | $ | 34,232,510 | 44,670,213 | $ | 446,702 | $ | 253,529,806 | $ | 1,071,069 | $ | (233,609,759 | ) | $ | 21,437,818 | |||||||||||||||||
Condensed Consolidated Statements of Cash Flows
(unaudited)
| Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (1,700,754 | ) | $ | (2,893,002 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 1,479,568 | 1,218,948 | ||||||
Interest from amortization of loan issuance costs | - | 38,312 | ||||||
Amortization of fair value of loan | - | 52,544 | ||||||
Change in fair value of acquisition earnout liabilities | 196,633 | 1,282,529 | ||||||
Loss on disposal of property and equipment | 30,849 | 3,999 | ||||||
Stock-based compensation on stock options, RSUs & RSAs, net | 1,801,199 | 359,661 | ||||||
Provision for credit losses | 48,827 | (5,390 | ) | |||||
Change in operating lease assets and liabilities | (18,687 | ) | (60,448 | ) | ||||
Inventory write-offs to allowance | 46,512 | - | ||||||
Deferred taxes | 910 | 555 | ||||||
Changes in operating assets and liabilities, net of acquisitions: | ||||||||
Trade accounts receivable | (118,609 | ) | (133,679 | ) | ||||
Other current assets | (16,506 | ) | 27,800 | |||||
Inventories | (13,527,486 | ) | (3,335 | ) | ||||
Prepaid expenses and deposits | 993,394 | 127,786 | ||||||
Accounts payable and accrued liabilities | 2,457,858 | (1,159,122 | ) | |||||
Net cash used in operating activities | (8,326,292 | ) | (1,142,842 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchase of property and equipment | (2,525,423 | ) | (77,014 | ) | ||||
Net cash used in investing activities | (2,525,423 | ) | (77,014 | ) | ||||
Cash flows from financing activities: | ||||||||
Proceeds from sale of common stock from Employee Stock Purchase Plan | 44,357 | - | ||||||
Proceeds from issuance of common stock under private equity placement, net of fees | - | 7,894,045 | ||||||
Proceeds from sale-leaseback of equipment | 591,974 | - | ||||||
Payments on loans payable | (28,291 | ) | (57,107 | ) | ||||
Repayment of finance lease obligations | (77,258 | ) | (55,398 | ) | ||||
Net cash provided by financing activities | 530,782 | 7,781,540 | ||||||
Effect of exchange rate on cash and cash equivalents | 50,443 | 68,698 | ||||||
Change in cash and cash equivalents | (10,270,490 | ) | 6,630,382 | |||||
Cash and cash equivalents, beginning of period | 93,204,655 | 4,877,036 | ||||||
Cash and cash equivalents, end of period | $ | 82,934,165 | $ | 11,507,418 | ||||
Supplemental disclosure of cash flow information: | ||||||||
Interest paid in cash | $ | 24,358 | $ | 177,963 | ||||
Income taxes paid | $ | 222,352 | $ | 56,282 | ||||
Supplemental disclosure of non-cash investing & financing activities: | ||||||||
Issuance of common stock for acquisition of AML, including earnouts | $ | 1,622,879 | - | |||||
Operating right-of-use assets acquired in exchange for operating lease liabilities | - | $ | 435,733 | |||||
Issuance of common stock for acquisition of Visimid | - | $ | 350,000 | |||||
SOURCE:
View the original press release on ACCESS Newswire